Y. Yarden and A. Ullrich, Growth Factor Receptor Tyrosine Kinases, Annual Review of Biochemistry, vol.57, issue.1, pp.443-78, 1988.
DOI : 10.1146/annurev.bi.57.070188.002303

N. Hynes and H. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors

M. Olayioye, R. Neve, and H. Lane, NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer, The EMBO Journal, vol.19, issue.13, pp.3159-67, 2000.
DOI : 10.1093/emboj/19.13.3159

K. Chung, J. Shia, and N. Kemeny, Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1813, 2005.
DOI : 10.1200/JCO.2005.08.037

M. Digiovanna, D. Stern, and S. Edgerton, Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients, Journal of Clinical Oncology, vol.23, issue.6
DOI : 10.1200/JCO.2005.09.055

Z. Wang, L. Zhang, and T. Yeung, Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation, Molecular Biology of the Cell, vol.10, issue.5, pp.1621-1657, 1999.
DOI : 10.1091/mbc.10.5.1621

J. Baulida, M. Kraus, and M. Alimandi, All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired, J Biol Chem, vol.271, pp.5251-5258, 1996.

A. Citri and Y. Yarden, EGF???ERBB signalling: towards the systems level, Nature Reviews Molecular Cell Biology, vol.96, issue.7, pp.505-521, 2006.
DOI : 10.1038/nrm1962

J. Dancey and H. Chen, Strategies for optimizing combinations of molecularly targeted anticancer agents, Nature Reviews Drug Discovery, vol.22, issue.8, pp.649-59, 2006.
DOI : 10.1038/nrd2089

S. Moulder, F. Yakes, and S. Muthuswamy, Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo, Cancer Res, vol.61, pp.8887-95, 2001.

J. Walshe, N. Denduluri, and A. Berman, A Phase II Trial with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressed Locally Advanced and Metastatic Breast Cancer, Clinical Breast Cancer, vol.6, issue.6, pp.535-544, 2006.
DOI : 10.3816/CBC.2006.n.009

. Larbouret-c, B. Robert, and I. Teulon, In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas, Clinical Cancer Research, vol.13, issue.11, pp.3356-62, 2007.
DOI : 10.1158/1078-0432.CCR-06-2302